283 related articles for article (PubMed ID: 26432853)
1. Expression of semaphorin 3A, semaphorin 7A and their receptors in multiple sclerosis lesions.
Costa C; Martínez-Sáez E; Gutiérrez-Franco A; Eixarch H; Castro Z; Ortega-Aznar A; Ramón Y Cajal S; Montalban X; Espejo C
Mult Scler; 2015 Nov; 21(13):1632-43. PubMed ID: 26432853
[TBL] [Abstract][Full Text] [Related]
2. Gene expression of semaphorin-3A, semaphorin-7A, neuropilin-1, plexin-C1, and β1 integrin in treated-multiple sclerosis patients.
Shapoori S; Mosayebi G; Ebrahimi Monfared M; Ghazavi A; Khansarinejad B; Farahani I; Ganji A
Neurol Res; 2020 Sep; 42(9):783-788. PubMed ID: 32497464
[TBL] [Abstract][Full Text] [Related]
3. Targeting semaphorins in MS as a treatment strategy to promote remyelination: A tale of mice, rats and men.
Kremer D; Hartung HP; Küry P
Mult Scler; 2015 Nov; 21(13):1616-7. PubMed ID: 26432852
[No Abstract] [Full Text] [Related]
4. Decreased Expression of Semaphorin 3A and Semaphorin 7A Levels and Its Association with Systemic Lupus Erythematosus.
Wang P; Mao YM; Liu LN; Zhao CN; Li XM; Pan HF
Immunol Invest; 2020 Feb; 49(1-2):69-80. PubMed ID: 31412748
[TBL] [Abstract][Full Text] [Related]
5. Semaphorin-3A,
Liu LN; Wang P; Zou YF; Xu Z; Cheng J; Zhang Y; Hu W; Pan HF
Autoimmunity; 2019 Jun; 52(4):161-167. PubMed ID: 31394943
[No Abstract] [Full Text] [Related]
6. Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design.
Gutiérrez-Franco A; Costa C; Eixarch H; Castillo M; Medina-Rodríguez EM; Bribián A; de Castro F; Montalban X; Espejo C
Clin Immunol; 2016 Feb; 163():22-33. PubMed ID: 26686462
[TBL] [Abstract][Full Text] [Related]
7. Semaphorin 7A initiates T-cell-mediated inflammatory responses through alpha1beta1 integrin.
Suzuki K; Okuno T; Yamamoto M; Pasterkamp RJ; Takegahara N; Takamatsu H; Kitao T; Takagi J; Rennert PD; Kolodkin AL; Kumanogoh A; Kikutani H
Nature; 2007 Apr; 446(7136):680-4. PubMed ID: 17377534
[TBL] [Abstract][Full Text] [Related]
8. Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.
Gutiérrez-Franco A; Eixarch H; Costa C; Gil V; Castillo M; Calvo-Barreiro L; Montalban X; Del Río JA; Espejo C
Mol Neurobiol; 2017 Aug; 54(6):4820-4831. PubMed ID: 27714632
[TBL] [Abstract][Full Text] [Related]
9. Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis.
Eixarch H; Gutiérrez-Franco A; Montalban X; Espejo C
Trends Mol Med; 2013 Mar; 19(3):157-64. PubMed ID: 23419749
[TBL] [Abstract][Full Text] [Related]
10. Assessment of semaphorin 3A and semaphorin 7A levels in primary Sjogren's syndrome.
Urhan E; Urhan AC; Dogan HO; Sahin A
Rheumatol Int; 2023 Jun; 43(6):1087-1092. PubMed ID: 36030414
[TBL] [Abstract][Full Text] [Related]
11. Vascular Semaphorin 7A Upregulation by Disturbed Flow Promotes Atherosclerosis Through Endothelial β1 Integrin.
Hu S; Liu Y; You T; Heath J; Xu L; Zheng X; Wang A; Wang Y; Li F; Yang F; Cao Y; Zhang H; van Gils JM; van Zonneveld AJ; Jo H; Wu Q; Zhang Y; Tang C; Zhu L
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):335-343. PubMed ID: 29269512
[TBL] [Abstract][Full Text] [Related]
12. Semaphorin 7A promotes endothelial permeability and inflammation via plexin C1 and integrin β1 in Kawasaki disease.
Huang J; Zhao C; Zhang S
BMC Pediatr; 2024 Apr; 24(1):285. PubMed ID: 38678170
[TBL] [Abstract][Full Text] [Related]
13. Semaphorin 7A as a potential immune regulator and promising therapeutic target in rheumatoid arthritis.
Xie J; Wang H
Arthritis Res Ther; 2017 Jan; 19(1):10. PubMed ID: 28109308
[TBL] [Abstract][Full Text] [Related]
14. Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
Costa C; Eixarch H; Martínez-Sáez E; Calvo-Barreiro L; Calucho M; Castro Z; Ortega-Aznar A; Ramón Y Cajal S; Montalban X; Espejo C
Am J Pathol; 2019 Mar; 189(3):665-676. PubMed ID: 30553833
[TBL] [Abstract][Full Text] [Related]
15. Endothelial semaphorin 7A promotes seawater aspiration-induced acute lung injury through plexin C1 and β1 integrin.
Zhang M; Yan X; Liu W; Sun R; Xie Y; Jin F
Mol Med Rep; 2017 Oct; 16(4):4215-4221. PubMed ID: 28765893
[TBL] [Abstract][Full Text] [Related]
16. Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models.
Boyd A; Zhang H; Williams A
Acta Neuropathol; 2013 Jun; 125(6):841-59. PubMed ID: 23595275
[TBL] [Abstract][Full Text] [Related]
17. Semaphorin 7A inhibits platelet production from CD34+ progenitor cells.
Jaimes Y; Gras C; Goudeva L; Buchholz S; Eiz-Vesper B; Seltsam A; Immenschuh S; Blasczyk R; Figueiredo C
J Thromb Haemost; 2012 Jun; 10(6):1100-8. PubMed ID: 22448926
[TBL] [Abstract][Full Text] [Related]
18. Semaphorin 7A modulates cytokine-induced memory-like responses by human natural killer cells.
Ghofrani J; Lucar O; Dugan H; Reeves RK; Jost S
Eur J Immunol; 2019 Aug; 49(8):1153-1166. PubMed ID: 31016720
[TBL] [Abstract][Full Text] [Related]
19. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions.
Nijland PG; Michailidou I; Witte ME; Mizee MR; van der Pol SM; van Het Hof B; Reijerkerk A; Pellerin L; van der Valk P; de Vries HE; van Horssen J
Glia; 2014 Jul; 62(7):1125-41. PubMed ID: 24692237
[TBL] [Abstract][Full Text] [Related]
20. The neuroimmune semaphorin-3A reduces inflammation and progression of experimental autoimmune arthritis.
Catalano A
J Immunol; 2010 Nov; 185(10):6373-83. PubMed ID: 20937848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
